Literature DB >> 22056226

Negative predictive value of positron emission tomography and computed tomography for stage T1-2N0 non-small-cell lung cancer: a meta-analysis.

Jingbo Wang1, Kathy Welch, Luhua Wang, Feng-Ming Spring Kong.   

Abstract

BACKGROUND: Nodal staging of non-small-cell lung cancer (NSCLC) is crucial in evaluation of prognosis and determination of therapeutic strategy. This study aimed to determine the negative predictive value (NPV) of combined positron emission tomography and computed tomography (PET-CT) in patients with stage I (T1-2N0) NSCLC and to investigate the possible risk factors for occult nodal disease.
METHODS: Studies investigating the performance of PET in conjunction with CT in the nodal staging of stage I NSCLC were identified in the MEDLINE database. The initiative of standards for reporting of diagnostic accuracy (STARD) was used to ensure study quality. Pathologic assessments through mediastinoscopy or thoracotomy were required as the reference standard for evaluation of PET-CT accuracy. Stata-based meta-analysis was applied to calculate the individual and pooled NPVs.
RESULTS: Ten studies with a total of 1122 patients with stage I (T1-2N0) NSCLC were eligible for analysis. The NPVs of combined PET and CT for mediastinal metastases were 0.94 in T1 disease and 0.89 in T2 disease. Including both T1 disease and T2 disease, the NPVs were 0.93 for mediastinal metastases and 0.87 for overall nodal metastases. Adenocarcinoma histology type (risk ratio [RR], 2.72) and high fluorine-18 (18F) fluorodeoxyglucose (FDG) uptake in the primary lesion were associated with greater risk of occult nodal metastases.
CONCLUSIONS: Although overall occult nodal metastases in clinical stage T1-2N0 NSCLC is not infrequent, combined PET and CT provide a favorable NPV for mediastinal metastases in T1N0 NSCLC, suggesting a low yield from routine invasive staging procedures for this subgroup of patients. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22056226      PMCID: PMC3346713          DOI: 10.1016/j.cllc.2011.08.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  46 in total

1.  Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.

Authors:  M A Farrell; H P McAdams; J E Herndon; E F Patz
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

2.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions.

Authors:  N C Gupta; G M Graeber; H A Bishop
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

Review 4.  Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer.

Authors:  Ozcan Birim; A Pieter Kappetein; Theo Stijnen; Ad J J C Bogers
Journal:  Ann Thorac Surg       Date:  2005-01       Impact factor: 4.330

5.  Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.

Authors:  Hye Kyeong Park; Kyeongman Jeon; Won-Jung Koh; Gee Young Suh; Hojoong Kim; O Jung Kwon; Man Pyo Chung; Kyung Soo Lee; Young Mog Shim; Joungho Han; Sang-Won Um
Journal:  Respirology       Date:  2010-11       Impact factor: 6.424

6.  Strategy for lymphadenectomy in lung cancer three centimeters or less in diameter.

Authors:  T Ishida; T Yano; K Maeda; S Kaneko; M Tateishi; K Sugimachi
Journal:  Ann Thorac Surg       Date:  1990-11       Impact factor: 4.330

7.  Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings.

Authors:  Jun Konishi; Koichi Yamazaki; Eriko Tsukamoto; Nagara Tamaki; Yuya Onodera; Toshiyuki Otake; Toshiaki Morikawa; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Masaharu Nishimura
Journal:  Respiration       Date:  2003 Sep-Oct       Impact factor: 3.580

8.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

9.  Relationship between primary tumor fluorodeoxyglucose uptake and nodal or distant metastases at presentation in T1 stage non-small cell lung cancer.

Authors:  Minghuan Li; Ningbo Liu; Man Hu; Fang Shi; Shuanghu Yuan; Pinliang Zhang; Zheng Fu; Guoren Yang; Jinming Yu
Journal:  Lung Cancer       Date:  2008-07-16       Impact factor: 5.705

Review 10.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors:  Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

View more
  31 in total

1.  PET-CT limitations in early stage non-small cell lung cancer: to whom more aggressive approach in radiotherapy and surgery should be directed?

Authors:  Lucyna Kepka; Joanna Socha
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

2.  Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer?

Authors:  Jean-Claude M Rwigema; Percy Lee
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

3.  Accuracy of positron emission tomography and computed tomography (PET/CT) in detecting nodal metastasis according to histology of non-small cell lung cancer.

Authors:  David E Smith; Julian Fernandez Aramburu; Alejandro Da Lozzo; Juan A Montagne; Enrique Beveraggi; Agustin Dietrich
Journal:  Updates Surg       Date:  2019-09-24

Review 4.  Current advances of endobronchial ultrasonography in the diagnosis and staging of lung cancer.

Authors:  Chao-Chi Ho; Ching-Kai Lin; Ching-Yao Yang; Lih-Yu Chang; Shu-Yung Lin; Chong-Jen Yu
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

5.  Cons: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Authors:  Herbert Decaluwé; Christophe Dooms
Journal:  Transl Lung Cancer Res       Date:  2016-06

6.  Pros: should a patient with stage IA non-small cell lung cancer undergo invasive mediastinal staging?

Authors:  Carme Obiols; Sergi Call
Journal:  Transl Lung Cancer Res       Date:  2016-06

7.  Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small (≤2 cm) Non-Small Cell Lung Cancer.

Authors:  Eric M Robinson; Ilkka K Ilonen; Kay See Tan; Andrew J Plodkowski; Matthew Bott; Manjit S Bains; Prasad S Adusumilli; Bernard J Park; Valerie W Rusch; David R Jones; James Huang
Journal:  Ann Thorac Surg       Date:  2019-08-31       Impact factor: 4.330

8.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Authors:  Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-03       Impact factor: 9.236

9.  Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.

Authors:  Kaoru Kaseda; Keisuke Asakura; Akio Kazama; Yukihiko Ozawa
Journal:  World J Surg       Date:  2016-12       Impact factor: 3.352

10.  Dual time point imaging for F18-FDG-PET/CT does not improve the accuracy of nodal staging in non-small cell lung cancer patients.

Authors:  Julian M M Rogasch; Ingo G Steffen; Sandra Riedel; Ivayla Apostolova; Heinz Wertzel; H Jost Achenbach; Ferdinand L G A Steinkrüger; Thomas Kalinski; Meinald Schultz; Jens Schreiber; Holger Amthauer; Christian Furth
Journal:  Eur Radiol       Date:  2015-11-11       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.